|
pubmed:abstractText |
ML 3000 ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid) is an inhibitor of both cyclooxygenase and 5-lipoxygenase in vitro, and shows promise as a novel non-steroidal anti-inflammatory drug (NSAID). Unlike conventional NSAIDs which are associated with gastric ulcerogenic effects, ML 3000 causes little or no damage to the gastric mucosa, even though it significantly depresses gastric prostaglandin synthesis.
|
|
pubmed:affiliation |
Gastroenterology and Hepatology Division, Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA. smolkaaj@musc.edu
|
